Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

BACKGROUND: In clinical practice the gold standard method to assess BRAF status in patients with metastatic melanoma is based on molecular assays. Recently, a mutation-specific monoclonal antibody (VE1), which detects the BRAF V600E mutated protein, has been developed. With this study we aimed to co...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:BMC Cancer
Auteurs principaux: Schirosi, Laura, Strippoli, Sabino, Gaudio, Francesca, Graziano, Giusi, Popescu, Ondina, Guida, Michele, Simone, Giovanni, Mangia, Anita
Format: Artigo
Langue:Inglês
Publié: BioMed Central 2016
Sujets:
Research Article
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC5116153/
https://ncbi.nlm.nih.gov/pubmed/27863476
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2951-4
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires